Another step ahead of Lilly! Novo Nordisk Wegovy approved by the US FDA for use in cardiovascular disease
美少女994
发表于 2024-3-10 09:37:30
1265
0
0
On Friday, March 8th local time, the US Food and Drug Administration (FDA) approved the celebrity weight loss drug Wegovy to reduce the risk of stroke and heart attack in overweight or obese adults.
As a new weight loss drug under the Danish pharmaceutical giant Novo Nordisk, Wegovy and the company's diabetes drug Ozempic contain the same active ingredient, namely semaglutide, which was originally designed to treat type 2 diabetes and belongs to a class of drugs called GLP-1 (glucagon like peptide-1).
The principle of action of drugs like Wegovy is to suppress the patient's appetite and slow down the gastric emptying rate. Experimental data shows that Wegovy not only helps patients lose an average of 15% of their weight (approximately 68 weeks), but also reduces the incidence of heart attacks, strokes, or heart disease deaths by 20%.
John Sharretts from the FDA Center for Drug Evaluation and Research stated that Wegovy is the first weight loss drug approved for cardiovascular disease.
Sharretts pointed out that adults with obesity and heart disease are at an increasing risk of cardiovascular complications, so providing a treatment plan that can effectively reduce such risks is a major advancement in public health.
Novo Nordisk responded on Friday that Wegovy's approval for cardiovascular disease represents a "crucial step towards addressing some of the most pressing issues of our time.". The company added that it is working hard to increase production capacity.
Novo Nordisk predicts that Wegovy will also be approved for cardiovascular disease in the European Union this year.
The FDA's decision is expected to help Novo Nordisk consolidate its leading position over its competitor, Lilly. Last November, Lilly's Tirzepatide injection was approved for weight loss in the United States under the drug name Zepbound.
The effectiveness of Zepbound in weight loss is not inferior to Wegovy, but it has not yet been proven to be effective in treating cardiovascular diseases.
It is worth mentioning that Novo Nordisk released the first phase trial data of its weight-loss oral drug, amybretin, this week. The data shows that after a 12 week trial, participants who used amycetin experienced an average weight loss of 13.1%. Wegovy can only reduce the patient's weight by about 6% after 12 weeks.
Martin Holst Lange, Executive Vice President of Research and Development at Novo Nordisk, stated that he believes the company can launch amyCretin before 2030.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- The GLP-1 theme fund in the US stock market triggers thinking. Who will be the next "Novo Nordisk"?
- Novo Nordisk responds that semaglutide may cause male impotence
- Will the reduced weight version of Smegglutide be limited in supply to the Chinese market? Novo Nordisk responds
- "Weight loss pills" are sold in limited quantities in China? Novo Nordisk's latest response
- Novo Nordisk's US stock fell more than 5% before trading
- Holding the 'miracle drug for weight loss', Novo Nordisk generates 133.4 billion DKK in revenue in H1 2024
- Oral "weight loss medication" further advances Novo Nordisk oral semaglutide weight loss phase III research success
- Is the dual monopoly situation of Novo Nordisk Lilly in danger? By 2029, there may be 16 GLP-1 weight loss drugs on the market
- Novo Nordisk faces US Senate inquiry over weight loss drug prices
- The US Senate questions whether the pricing of the "weight loss miracle drug" is too high. Nuo and Nuo De respond that lowering the price is useless
-
大雪と網易が「複合」した後、大雪系傘下のゲームが次々と国服に復帰しつつあり、9月25日、魔獣世界に続き、大雪系ゲームの「現金牛」、カードゲーム「炉石伝説」が正式に国服に復帰した。午前7時26分、新京報貝殻 ...
- vvsky
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
上証報中国証券網(何奎記者)は9月25日、国内頭部保険電子商取引サービスプラットフォームの慧択氏が米国株の開場前に発表した2024年第2四半期の未監査業績報告によると、上半期の慧択全プラットフォームによる総 ...
- 18010063851
- 前天 11:44
- 支持
- 反对
- 回复
- 收藏
-
百勝中国9月23日のニュースによると、百勝中国と保利発展ホールディングスはこのほど、広州保利発展広場で戦略協力協定に調印した。双方はそれぞれのビジネス分野での技術、管理、ブランドの優位性を十分に利用し、 ...
- 寒郁轩良
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
【世界市場】1、納指は0.04%、ダウは0.70%、スタンダードは0.19%下落した。2、英偉達は2%超上昇し、美光科技の株価は10%超上昇した。3、ナスダック中国の金龍指数は2.80%、蔚来は5%近く下落した。4、国際原油価格は ...
- 虚空一粒沙2017
- 前天 21:42
- 支持
- 反对
- 回复
- 收藏